title: Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents.
abstract: OBJECTIVE
  Pancreatic metastases (PM) from renal cell carcinoma (RCC) have been associated with long-term survival. The aim of this study was to evaluate the outcome of RCC patients with multiple glandular metastases (MGM) treated with targeted therapies (TTs).
  
  
  METHODS
  Sixty-four MGM patients treated between 1993 and 2014 were retrospectively identified from a database of 274 RCC patients with PM from 11 European centers. The survival of MGM patients was compared with that of both patients with PM only and a cohort of 325 RCC patients with non-GM (control group) treated with TTs. Survival was estimated using the Kaplan-Meier method and was statistically compared using the log-rank test.
  
  
  RESULTS
  Fifty-six patients (88%) had at least 2 MGM, 7 patients (11%) had 3 MGM and 1 patient had 4 MGM, while non-GM were present in the remaining patients. The median overall survival (OS) was 54.2 months for MGM and 73.4 months for patients with PM only. The median OS in the control group was 22.7 months and statistically inferior to both MGM (p < 0.001) and PM patients (p < 0.001).
  
  
  CONCLUSIONS
  MGM from RCC are associated with a remarkable survival. Despite some limitations, these findings suggest that GM might be considered a predictor of a favorable prognosis.
authors.affiliation: Medical Oncology 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Grassi
authors.forename: Ludovic
authors.initials: L
authors.lastname: Doucet
authors.forename: Palma
authors.initials: P
authors.lastname: Giglione
authors.forename: Viktor
authors.initials: V
authors.lastname: Grünwald
authors.forename: Bohuslav
authors.initials: B
authors.lastname: Melichar
authors.forename: Luca
authors.initials: L
authors.lastname: Galli
authors.forename: Ugo
authors.initials: U
authors.lastname: De Giorgi
authors.forename: Roberto
authors.initials: R
authors.lastname: Sabbatini
authors.forename: Cinzia
authors.initials: C
authors.lastname: Ortega
authors.forename: Matteo
authors.initials: M
authors.lastname: Santoni
authors.forename: Aristotelis
authors.initials: A
authors.lastname: Bamias
authors.forename: Elena
authors.initials: E
authors.lastname: Verzoni
authors.forename: Lisa
authors.initials: L
authors.lastname: Derosa
authors.forename: Hana
authors.initials: H
authors.lastname: Studentova
authors.forename: Luca
authors.initials: L
authors.lastname: Porcu
authors.forename: Filippo
authors.initials: F
authors.lastname: De Braud
authors.forename: Camillo
authors.initials: C
authors.lastname: Porta
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Procopio
mesh_terms: D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D005060:Europe; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D009377:Multiple Endocrine Neoplasia / Q000188:drug therapy* / Q000556:secondary; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
keywords: Glandular metastases; Renal cell carcinoma; Targeted therapy; Tyrosine kinase inhibitors